Sander M. Botter
Sander M. Botter has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Walter Born
Department of Orthopedics Balgrist University Hospital Zurich Switzerland
2 shared publications- Ana Gvozdenovic
Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology Zurich (ETH Zurich), Zurich, Switzerland
1 shared publication - Andrea Stephanie Leuthardt
Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
1 shared publication - Andreas Lodberg
Department of Biomedicine, Aarhus University, Aarhus, Denmark
1 shared publication - Anke Strölin
Department of Dermatology Eberhard Karls University Tuebingen Germany
1 shared publication - Annette Høgh
Vascular Research Unit, Department of Vascular Surgery, Viborg Regional Hospital, Viborg, Denmark
1 shared publication
Latest Publications
- Open Access
Evidence of maternal resilience in two mouse strains in the context of permanent mouse breeding strategies
Breeding female mice represent an essential but often overlooked workforce sustaining biomedical research. Despite their central role, the physiological and behavioral consequences of repeated reproductive cycles have been poorly characterized, in part because breeding animals fall outside the primary focus of laboratory animal welfare efforts, and in part because meaningful welfare readouts for laboratory rodents remain an active area of research. Here we report findings from an exploratory phenotypic study designed to capture a composite picture of maternal health in female mice of two commonly used inbred strains, BALB/cByJ and C57BL/6J, exposed to one, two, or four consecutive cycles of pregnancy and lactation, with age-matched virgin females as controls. Assessments were conducted during the final lactation period and in the five weeks following weaning, spanning behavioral, metabolic, and physiological readouts selected for their known sensitivity to reproductive or environmental challenge. Repeated reproduction altered maternal physiology, most clearly in bone microstructure, which showed progressive and dose-dependent changes across parity levels, and more subtly in body mass, energy balance, and glucose homeostasis. Behavioral readouts of maternal motivation, by contrast, remained largely stable across reproductive load. Strain differences were pervasive, underscoring that reproductive adaptation is not uniform across standard laboratory models and cautioning against generalizing from a single strain. Together, the data suggest that mouse dams demonstrate considerable resilience under intensive breeding conditions, while also highlighting that breeding shapes the maternal body in ways that accumulate across reproductive cycles and deserve greater scientific attention.
Open AccessEvidence of maternal resilience in two mouse strains in the context of permanent mouse breeding strategies
Breeding female mice represent an essential but often overlooked workforce sustaining biomedical research. Despite their central role, the physiological and behavioral consequences of repeated reproductive cycles have been poorly characterized, in part because breeding animals fall outside the primary focus of laboratory animal welfare efforts, and in part because meaningful welfare readouts for laboratory rodents remain an active area of research. Here we report findings from an exploratory phenotypic study designed to capture a composite picture of maternal health in female mice of two commonly used inbred strains, BALB/cByJ and C57BL/6J, exposed to one, two, or four consecutive cycles of pregnancy and lactation, with age-matched virgin females as controls. Assessments were conducted during the final lactation period and in the five weeks following weaning, spanning behavioral, metabolic, and physiological readouts selected for their known sensitivity to reproductive or environmental challenge. Repeated reproduction altered maternal physiology, most clearly in bone microstructure, which showed progressive and dose-dependent changes across parity levels, and more subtly in body mass, energy balance, and glucose homeostasis. Behavioral readouts of maternal motivation, by contrast, remained largely stable across reproductive load. Strain differences were pervasive, underscoring that reproductive adaptation is not uniform across standard laboratory models and cautioning against generalizing from a single strain. Together, the data suggest that mouse dams demonstrate considerable resilience under intensive breeding conditions, while also highlighting that breeding shapes the maternal body in ways that accumulate across reproductive cycles and deserve greater scientific attention.
- Open Access
- 1 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 631-644.e22
Development of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics
- 1 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 631-644.e22
Open AccessDevelopment of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics
- Open Access
- 19 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14281
Neuro-Urology and Biobanking: An Integrated Approach for Advancing Research and Improving Patient Care
Understanding the molecular mechanisms underlying neuro-urological disorders is crucial for the development of targeted therapeutic interventions. Through the establishment of comprehensive biobanks, researchers can collect and store various biological specimens, including urine, blood, tissue, and DNA samples, to study these mechanisms. In the context of neuro-urology, biobanking facilitates the identification of genetic variations, epigenetic modifications, and gene expression patterns associated with neurogenic lower urinary tract dysfunction. These conditions often present as symptoms of neurological diseases such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, spinal cord injury, and many others. Biobanking of tissue specimens from such patients is essential to understand why these diseases cause the respective symptoms and what can be done to alleviate them. The utilization of high-throughput technologies, such as next-generation sequencing and gene expression profiling, enables researchers to explore the molecular landscape of these conditions in an unprecedented manner. The development of specific and reliable biomarkers resulting from these efforts may help in early detection, accurate diagnosis, and effective monitoring of neuro-urological conditions, leading to improved patient care and management. Furthermore, these biomarkers could potentially facilitate the monitoring of novel therapies currently under investigation in neuro-urological clinical trials. This comprehensive review explores the synergistic integration of neuro-urology and biobanking, with particular emphasis on the translation of biobanking approaches in molecular research in neuro-urology. We discuss the advantages of biobanking in neuro-urological studies, the types of specimens collected and their applications in translational research. Furthermore, we highlight the importance of standardization and quality assurance when collecting samples and discuss challenges that may compromise sample quality and impose limitations on their subsequent utilization. Finally, we give recommendations for sampling in multicenter studies, examine sustainability issues associated with biobanking, and provide future directions for this dynamic field.
- 19 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14281
Open AccessNeuro-Urology and Biobanking: An Integrated Approach for Advancing Research and Improving Patient Care
Understanding the molecular mechanisms underlying neuro-urological disorders is crucial for the development of targeted therapeutic interventions. Through the establishment of comprehensive biobanks, researchers can collect and store various biological specimens, including urine, blood, tissue, and DNA samples, to study these mechanisms. In the context of neuro-urology, biobanking facilitates the identification of genetic variations, epigenetic modifications, and gene expression patterns associated with neurogenic lower urinary tract dysfunction. These conditions often present as symptoms of neurological diseases such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, spinal cord injury, and many others. Biobanking of tissue specimens from such patients is essential to understand why these diseases cause the respective symptoms and what can be done to alleviate them. The utilization of high-throughput technologies, such as next-generation sequencing and gene expression profiling, enables researchers to explore the molecular landscape of these conditions in an unprecedented manner. The development of specific and reliable biomarkers resulting from these efforts may help in early detection, accurate diagnosis, and effective monitoring of neuro-urological conditions, leading to improved patient care and management. Furthermore, these biomarkers could potentially facilitate the monitoring of novel therapies currently under investigation in neuro-urological clinical trials. This comprehensive review explores the synergistic integration of neuro-urology and biobanking, with particular emphasis on the translation of biobanking approaches in molecular research in neuro-urology. We discuss the advantages of biobanking in neuro-urological studies, the types of specimens collected and their applications in translational research. Furthermore, we highlight the importance of standardization and quality assurance when collecting samples and discuss challenges that may compromise sample quality and impose limitations on their subsequent utilization. Finally, we give recommendations for sampling in multicenter studies, examine sustainability issues associated with biobanking, and provide future directions for this dynamic field.
- Open Access
- 12 November 2020
- Published by Wiley in Cancer Medicine
- Vol. 10 (1) , 286-296
Inhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma
Osteosarcoma is a cancer of pathological bone remodeling with high mortality and severe comorbidity. New therapies are urgently needed. Activin A, a member of the transforming growth factor β (TGFβ) superfamily, has been suggested to stimulate proliferation and invasion of osteosarcoma cells in vitro, thus representing a potential therapeutic target. In this study, inhibition of the activin receptor signaling pathway was explored as a therapy for osteosarcoma. In a murine intratibial osteosarcoma xenograft model, two types of inhibitors were tested: (a) a soluble activin type IIA decoy receptor (ActRIIA‐mFc), or (b) a modified variant of follistatin (FSTΔHBS‐hFc), either alone or in combination with a bisphosphonate. Both inhibitors reduced primary tumor development by nearly 50% compared to vehicle treatment. When ActRIIA‐mFc was combined with bisphosphonate, the effect on tumor size became even more pronounced (78% reduction vs. vehicle). Moreover, FSTΔHBS‐hFc increased body weight in the face of tumor progression (14% increase vs. vehicle), and ActRIIA‐mFc reduced the number of lung metastases when combined with bisphosphonate. The present study demonstrates a novel approach to treating osteosarcoma and encourages further investigation of inhibition of the activin receptor signaling pathway as an intervention against the disease.
- 12 November 2020
- Published by Wiley in Cancer Medicine
- Vol. 10 (1) , 286-296
Open AccessInhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma
Osteosarcoma is a cancer of pathological bone remodeling with high mortality and severe comorbidity. New therapies are urgently needed. Activin A, a member of the transforming growth factor β (TGFβ) superfamily, has been suggested to stimulate proliferation and invasion of osteosarcoma cells in vitro, thus representing a potential therapeutic target. In this study, inhibition of the activin receptor signaling pathway was explored as a therapy for osteosarcoma. In a murine intratibial osteosarcoma xenograft model, two types of inhibitors were tested: (a) a soluble activin type IIA decoy receptor (ActRIIA‐mFc), or (b) a modified variant of follistatin (FSTΔHBS‐hFc), either alone or in combination with a bisphosphonate. Both inhibitors reduced primary tumor development by nearly 50% compared to vehicle treatment. When ActRIIA‐mFc was combined with bisphosphonate, the effect on tumor size became even more pronounced (78% reduction vs. vehicle). Moreover, FSTΔHBS‐hFc increased body weight in the face of tumor progression (14% increase vs. vehicle), and ActRIIA‐mFc reduced the number of lung metastases when combined with bisphosphonate. The present study demonstrates a novel approach to treating osteosarcoma and encourages further investigation of inhibition of the activin receptor signaling pathway as an intervention against the disease.
- Open Access
Remineralization of Artificial Dentin Caries Using Dentin and Enamel Matrix Proteins
To assess the remineralizing potential of dentin matrix proteins and enamel matrix derivatives (DMPs and EMDs) after application on artificially induced dentin lesions, given the hypothesis that these materials increase the mineral uptake, binding, and mineralization. Forty-eight caries-free human premolars were used. Teeth were cut, polished, and embedded, leaving an open window on the root surface, of which one-third was covered with a flowable composite to preserve the healthy untreated dentin. Then, samples were demineralized in Buskes solution for 33 days. A micro-CT scan prior to treatment was performed. Next, the samples were randomly allocated into four groups: (A) An untreated negative control (CON), (B) application of porcine dentin matrix proteins (DMP), (C) treatment with enamel matrix derivatives (EMD, Emdogain, Straumann), and (D) amine fluoride application (AMF, Elmex fluid, GABA). All samples were placed in artificial saliva for 21 days. A second micro-CT scan was performed, after which the change in gray scaling within a defined region of interest (0.25 mm3) was analyzed. ANCOVA was applied to discover statistical differences between the different treatments. Both, treatment with AMF; (P = 0.011 versus CON) as well as with DMP (P = 0.043 versus CON) yielded a statistically significant difference compared to the control treatment. EMD treatment was not found to differ (P > 0.05). Mainly the top layer of the defects showed clear signs of remineralization, which was also evident in CON. This study was able to visually confirm the remineralization potential of demineralized dentin especially after DMP application, which, however, did not outperform AMF. Based on this, additional studies combining proteins and fluorides are now warranted and ongoing.
Open AccessRemineralization of Artificial Dentin Caries Using Dentin and Enamel Matrix Proteins
To assess the remineralizing potential of dentin matrix proteins and enamel matrix derivatives (DMPs and EMDs) after application on artificially induced dentin lesions, given the hypothesis that these materials increase the mineral uptake, binding, and mineralization. Forty-eight caries-free human premolars were used. Teeth were cut, polished, and embedded, leaving an open window on the root surface, of which one-third was covered with a flowable composite to preserve the healthy untreated dentin. Then, samples were demineralized in Buskes solution for 33 days. A micro-CT scan prior to treatment was performed. Next, the samples were randomly allocated into four groups: (A) An untreated negative control (CON), (B) application of porcine dentin matrix proteins (DMP), (C) treatment with enamel matrix derivatives (EMD, Emdogain, Straumann), and (D) amine fluoride application (AMF, Elmex fluid, GABA). All samples were placed in artificial saliva for 21 days. A second micro-CT scan was performed, after which the change in gray scaling within a defined region of interest (0.25 mm3) was analyzed. ANCOVA was applied to discover statistical differences between the different treatments. Both, treatment with AMF; (P = 0.011 versus CON) as well as with DMP (P = 0.043 versus CON) yielded a statistically significant difference compared to the control treatment. EMD treatment was not found to differ (P > 0.05). Mainly the top layer of the defects showed clear signs of remineralization, which was also evident in CON. This study was able to visually confirm the remineralization potential of demineralized dentin especially after DMP application, which, however, did not outperform AMF. Based on this, additional studies combining proteins and fluorides are now warranted and ongoing.